On August 10, 2020, Acelrx Pharmaceuticals, Inc. (NASDAQ:ACRX) announced that it has received approval from the U.S. Department of Defense for DSUVIA for the management of acute pain in adults during dental and oral surgery.  According to the company's press release, filed in the U.S. District Court for the Southern District of New York, DSUVIA was approved in April 2019 for the management of acute pain in adult patients during dental and oral surgery.  The company also announced in April 2019 that it had received approval for DSUVIA in all of the U.S. Army sets, kits and outfits or SKOs associated with future deployments.  The company also announced in April that it had received approval from the Department of Defense for DSUVIA in all of the hospital and ambulatory surgery centers.  The company also announced in May that it was going to market DSUVIA to hospitals and ambulatory surgery centers in the U.S.  The company's CEO, Vince Angotti, and CFO, Debra Angotti, have agreed to the entry of a final judgment that permanently enjoins them from future violations of the antifraud provisions of Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.  The settlement is subject to court approval.  The SEC's continuing investigation is being conducted by Cynthia Folkes, Ashley Higgins, and Evan Seigerman of the Chicago Regional Office.  The litigation will be led by Debra Angotti and Ms. Folkes.  The SEC appreciates the assistance of the U.S. Attorney's Office for the Southern District of New York, the Federal Bureau of Investigation, and the U.S. Secret Service.  The SEC's Office of Investor Education and Advocacy has issued anÂ Investor AlertÂ to encourage investors to check the background of anyone selling or offering them an investment using the free and simple search tool onÂ Investor.gov.